BTCYOTCSurgical & Medical Instruments & ApparatusFiscal year ends March 31
BIOTRICITY INC.
Financials through Q1 FY2027, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 19, 2026
$0.05+0.00 (+8.70%)
Close on Oct 19, 2026
- Market cap
- $1.15M
- P/E (TTM)
- –
- Dividend yield
- –
BIOTRICITY INC. revenue by segment
By business segment
By product or service
| Revenue | TTM Q1 27 | TTM Q4 26 | TTM Q3 26 | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Technology Fees [Member] | $15.24M | $14.44M | $13.64M | $13.39M | $12.95M | $12.59M | $12.44M | $11.83M | $11.50M | $11.25M | $10.84M | $10.32M | 92.9% | +17.7% |
| Device Sales [Member] | $1.17M | $1.56M | $1.81M | $1.69M | $1.52M | $1.20M | $829.72K | $790.07K | $747.88K | $814.23K | $785.01K | $798.12K | 7.1% | -23.2% |
By region
From the segment and revenue-disaggregation notes of Biotricity's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.